Enema

Grindr Presents: Who's The Asshole?, A New Sex-Positive Podcast Hosted by Katya

Retrieved on: 
Wednesday, February 7, 2024
Love, Emotion, Communication, Asshole, Homophobia, Enema, Humour, Hook-up

WEST HOLLYWOOD, Calif., Feb. 7, 2024 /PRNewswire/ -- Ever wondered, "Am I the asshole?" Well… we've got answers. Today, Grindr launched Who's The Asshole?, a provocative and sex-positive series hosted by beloved drag legend, Katya Zamolodchikova. With a guest lineup of icons and trailblazers, the world's most popular networking app for the LGBTQ+ community is providing an unfiltered and judgment-free space to explore the messy gray areas of lust, love, and everything in between…the cheeks.

Key Points: 
  • Today, Grindr launched Who's The Asshole?, a provocative and sex-positive series hosted by beloved drag legend, Katya Zamolodchikova.
  • "I love diving deep into the dirty, juicy, filthy tea, so when Grindr said I could be paid to do it?!
  • There are so many topics people are too embarrassed to discuss, but I have no shame to go there," says Katya.
  • premieres on February 15, 2024 and can be viewed on YouTube and streamed wherever you get your podcasts.

Two-Thirds of Americans Are Living With Gut issues, Unaware of the Health Consequences

Retrieved on: 
Wednesday, May 24, 2023
Enema, Gut, Diet, Diabetes, Ipsos, Stroke, Food, Quality of life, Laxative, Woman, Grain boundary strengthening, Vegetable, Abdominal pain, MDVIP, Nutritional science, Yogurt, Bloating, Bacteria, Probiotic, Poultry farming, Birth control, Dietary supplement

BOCA RATON, Fla., May 24, 2023 /PRNewswire/ -- When it comes to gut health, Americans are not keeping theirs in check. A new study from MDVIP and Ipsos finds two-thirds of adults experience recurrent digestive symptoms like gas, bloating and abdominal pain, but few seek care from their doctor. The survey also reveals that most people are not aware of the importance of gut health and ways to improve it, with over half (52%) saying they are confused by the deluge of information on diet and nutrition and 85% of Americans failing a Gut IQ quiz.

Key Points: 
  • 2 in 3 Americans are unfamiliar with the term "gut microbiome," which are the trillions of bacteria living in the digestive tract.
  • 3 in 5 Americans don't know that an unhealthy gut can increase heart attack/stroke and dementia risk.
  • 71% of Americans don't know antibiotics can kill good gut bacteria in addition to the bad.
  • "Start with the dynamic duo of probiotics and prebiotics which work together in promoting the good bacteria in your gut.

AMEND PET AND ASSOCIATION OF SHELTER VETERINARIANS PARTNER TO EXPAND ACCESS TO FECAL MICROBIOTA TRANSPLANT FOR TREATING DIARRHEA IN SHELTER PETS

Retrieved on: 
Wednesday, May 10, 2023
Enema, Partnership, Dysbiosis, Diarrhea, Veterinarian, FMT, Trust, Animal, Patient, ASV, Dog, Pet, Colonoscopy, Health, Veterinary medicine, Management

SEATTLE, May 10, 2023 /PRNewswire/ -- Amend Pet ("the company"), a microbiome solutions company, today announced the launch of its partnership with the Association of Shelter Veterinarians (ASV) to provide ASV members affordable, easy-to-administer Fecal Microbiota Transplant Therapy (FMT) and microbiome testing to assess dogs for dysbiosis. FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.

Key Points: 
  • FMT is a proven treatment for recurrent diarrhea in pets, but until now has been too labor intensive and costly for veterinarians to widely utilize.
  • Amend Pet's FMT capsule device and testing solution allows veterinarians to prepare multiple transplant regimens in 5-10 minutes in their own facility from pet donors they know and trust.
  • "We are excited to support ASV Veterinarians who maximize limited resources to provide a vital service for countless animals", said Mike Goonewardene, CEO of Amend Pet.
  • "Our partnership with Amend Pet opens the door to innovative products and services in a vital area of care, digestive health, for animals residing in shelters across the country".

Ferring Pharmaceuticals' 1st in Class C.diff Treatment, Rebyota, Experiences a Positive Early Launch Ahead of Potential Competition, According to Spherix Global Insights

Retrieved on: 
Friday, March 17, 2023
Enema, Ferring Pharmaceuticals, Macrogol, Clostridioides, Physician, Infection, Gastroenterology, Research, Temperature, Launch, FMT, Patient, Fecal microbiota transplant, Clostridioides difficile, FDA, Recurrence, Disease, Pharmaceutical industry

EXTON, Pa., March 17, 2023 /PRNewswire/ -- When the FDA approved Rebyota, a new class of Clostridioides Difficile (C.diff) treatment, Ferring Pharmaceuticals ushered in the first significant breakthrough doctors treating the disease have seen in years. Rebyota falls in the class of therapy known as Fecal Microbiota Transplant, or FMT, a therapy over 60% of treating gastroenterologists believe will dramatically change the paradigm of C.diff treatment in the next five years, according to research from Spherix Global Insights Market Dynamix™ Clostridioides Difficile (US) service.

Key Points: 
  • At least two additional FMT treatments are in development for C.diff, including Aimmune/Seres' SER-109 and Vedanta Biosciences' VE303.
  • With a first to market advantage, Ferring's Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch.
  • As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
  • A few headwinds Ferring may be facing with Rebyota include its mode of administration, and storage and handling requirements.

Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022

Retrieved on: 
Monday, October 24, 2022
SAN, Royal Adelaide Hospital, Colon, Disease, Therapy, SEC, Self-microemulsifying drug delivery system, American College of Gastroenterology, Annual report, Patient, Result, Research, Tissue, Financial condition report, GI, Nasdaq, Precision medicine, Private Securities Litigation Reform Act, Goal, Trial of the century, Analysis, ACG, DDS, Mater Group, Pharmacokinetics, Fasting, UC, IBD, Safety, Adalimumab, GLOBE, Ulcerative colitis, Â, Serri, Sardinia, Inflammatory bowel disease, Enema, American College, COVID-19, Medical device, Pharmaceutical industry, Dietary supplement

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 2126, 2022.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 2126, 2022.
  • Biora Therapeutics targeted therapeutics platform utilizes a novel approach that could improve IBD patient outcomes by enabling delivery of therapeutics directly to the site of disease.
  • Bioras Drug Delivery System (DDS) is an ingestible capsule designed for targeted delivery of therapeutics to improve treatment of IBD.
  • Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Human Microbiome Market Trends and Global Forecasts 2022-2035: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 7, 2022
Health, General Health, Molecule, Marketing, Type, CMO, FMT, Associate, Business development, Partnership, Algorithm, Therapy, Former, Primary hyperoxaluria, FDA, Growth, Feces, Necrotizing enterocolitis, Diagnosis, Human microbiome, Infection, Adoption, Prevalence, Clinical trial, Investor, Colonoscopy, CDI, Degenerative disease, Enema, Medical device, Pharmaceutical industry, Risk management, Antibiotics, Fine chemical, Management, Innovation, Research

The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade.
  • What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
  • How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?

Training Manikins Market Forecast Report 2021-2028 - Opportunities in the Application of Robotics, Artificial Intelligence, Augmented Reality, and 3D Printing - ResearchAndMarkets.com

Retrieved on: 
Friday, April 22, 2022
Technology, Medical Devices, Infectious Diseases, Engineering, Other Technology, Manufacturing, Practice Management, Electronic Design Automation, General Health, Health, Neonatal Resuscitation Program, Awareness, BP, Heart sounds, Obstetrics, Mannequin, Intubation, COVID-19, Pediatrics, Resuscitation, Hospital, CAGR, Enema, Death, EKG, Pediatrics (journal), Growth, CPR, OHCA, Application, Technology, Maintenance, Infant, American Academy, Prevalence, Health, NRP, Medicine

The "Training Manikins Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Training Manikins Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, and Application" report has been added to ResearchAndMarkets.com's offering.
  • The Training Manikins market is projected to reach US$ 1,235.61 million by 2028 from US$ 2,603.89 million in 2021.
  • The growth of the training manikins market is attributed to technological advancements and the increasing prevalence of out-of-hospital cardiac arrests and cardiopulmonary resuscitation training and awareness programs.
  • Based on type, the global training manikins market is segmented into CPR training manikins, infant manikins, and others.

MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Pharmaceutical, Health, Graft-versus-host disease, Maintenance, OSD, MET, Letter, Biomarker, Multimedia, Maat, Company, Cancer, Patient, Euronext Paris, Survival, CGMP, CDMO, Immunotherapy, CEO, Health, Saint-Quentin-Fallavier, Therapy, Bioproduction, Ecosystem, Enema, Partnership, R, Certification, Forward-looking statement, Pharmaceutical industry, Fine chemical, MaaT Pharma, Skyepharma, MAAT PHARMA, SKYEPHARMA

The plant will allow MaaT Pharma to increase its manufacturing capacities ten-fold in order to support clinical and commercial development by 2030.

Key Points: 
  • The plant will allow MaaT Pharma to increase its manufacturing capacities ten-fold in order to support clinical and commercial development by 2030.
  • We can look forward to expanding our product portfolio for cancer patients with serenity," commented Herv Affagard, Co-founder and CEO of MaaT Pharma.
  • David Lescuyer, Managing Director of Skyepharma added, "SkyeHub will increase cGMP production capacity for microbiome-based drugs in France.
  • The companys Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations.

MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study

Retrieved on: 
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biomarker, Euronext Paris, Survival, Forward-looking statement, Patient, Human, Degenerative disease, Safety, Incidence, MET, CIMON, OTU, Operational taxonomic unit, Maat, CEO, Data monitoring committee, Acute myeloid leukemia, Bacteria, Graft-versus-host disease, Enema, Company, 16S, CGMP, MD, Capsule, Cancer, Pharmaceutical industry, Dietary supplement, Antibiotics, MaaT033, MaaT Pharma, MAAT033, MAAT PHARMA

Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.

Key Points: 
  • Complete results from the Phase 1b CIMON trial are expected in the first half of 2022.
  • These interim results are an important milestone for MaaT Pharma as MaaT033 is our second drug candidate and our first oral formulation, to demonstrate proof of engraftment in humans, said Herv Affagard, CEO and co-founder of MaaT Pharma.
  • MaaT033 is intended to improve survival outcomes in hemato-oncology patients receiving allo-HSCT by protecting and restoring their gut microbiome.
  • We look forward to further exploring the data from CIMON and preparing for a Phase 2/3 trial start.

MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Tuesday, November 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Society, Phase, Cancer, Biomarker, Graft-versus-host disease, MET, Degenerative disease, Hospital, CGMP, ASH, Sorbonne University, Euronext Paris, Enema, EAP, Treatment, Immune reconstitution inflammatory syndrome, GI, Company, Survival, Patient, Head, Pharmaceutical industry

The HERACLES results include data from 24 patients with grade III-IV, steroid-resistant, gastrointestinal (GI)-predominant, acute Graft-versus-Host-Disease (aGvHD) that were treated with MaaT013 as second line therapy.

Key Points: 
  • The HERACLES results include data from 24 patients with grade III-IV, steroid-resistant, gastrointestinal (GI)-predominant, acute Graft-versus-Host-Disease (aGvHD) that were treated with MaaT013 as second line therapy.
  • MaaT013 is a high-richness, high-diversity Microbiome Ecosystem Therapy (MET) derived from pooled donations from strictly vetted healthy individuals and is presented as an enema.
  • Title: Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program
    Session Name: 722.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.